Aroa Biosurgery Ltd (ASX: ARX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Aroa Biosurgery Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $254.15 million
P/E Ratio 23.47
Dividend Yield 0.00%
Shares Outstanding 343.44 million
Earnings per share -0.003
Dividend per share N/A
Year To Date Return -33.80%
Earnings Yield 4.26%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Aroa Biosurgery Ltd (ASX: ARX)
    Latest News

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Aroa Biosurgery, Bank of Queensland, Champion Iron, and Terracom shares are falling

    These ASX shares are ending the month deep in the red.

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Morgans says these small cap ASX healthcare shares are buys with 50% upside

    Looking for big returns? Then you might want to look at the small side of the market.

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Broker Notes

    Buy these 2 ASX health-tech shares that are ready to rocket: Wilson

    Consumers still want to stay healthy even through tough economic times.

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    52-Week Highs

    4 ASX All Ordinaries shares hitting new 52-week highs today

    Do you know the coal and healthcare shares trading at 12-month highs?

    Read more »

    a person stands on top of a mountain with hands raised above their head gazing on an amazing sunrise over the landscape and above the clouds.
    52-Week Highs

    5 ASX All Ords shares cracking new 52-week highs on Tuesday

    Are your investments trading at their highest point in more than 12 months today?

    Read more »

    Two people climb to the summit and raise their arms in success as the sun rises brightly over the mountains.
    52-Week Highs

    2 ASX All Ords shares cracking new 52-week highs on Tuesday

    Do these healthcare shares have a place in your portfolio?

    Read more »

    A woman looks internationally at a digital interface of the world.
    Broker Notes

    Buy 2 ASX shares for cutting-edge tech changing the world: expert

    Wilson analyst picks a pair of stocks that are using amazing technologies to produce innovative solutions to global problems.

    Read more »

    Two happy scientists analysing test results in a lab
    Healthcare Shares

    The ASX All Ords share that's a better, cheaper buy than Polynovo: Wilsons

    Could this one ASX healthcare share be set for growth?

    Read more »

    A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
    Share Gainers

    Why Aroa Biosurgery, Cettire, Estia Health, and Weebit Nano shares are rising

    These ASX shares are rising on Tuesday...

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Growth Shares

    3 hot small-cap ASX growth shares Firetrail's backing right now

    Do you want to invest in some emerging businesses while they're cheap? Here's a trio that are looking good.

    Read more »

    ASX shares Business man marking buy on board and underlining it
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Here's why brokers rate these ASX shares as buys...

    Read more »

    Man in whit coat after explosion.
    Healthcare Shares

    2 ASX healthcare shares set to explode 70% in 2022: expert

    Biotech and health stocks can fluctuate wildly, but when things go right they can be very rewarding for investors. Here's…

    Read more »

    Frequently Asked Questions

    No, Aroa Biosurgery does not pay shareholder dividends at this time.

    Aroa Biosurgery Ltd listed on the ASX on 24 July 2020.

    ARX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Aroa Biosurgery Ltd

    Aroa Biosurgery Ltd (ASX:  ARX) is a New Zealand-based biomedical company specialising in  soft tissue regeneration. It develops, manufactures, and distributes medical and surgical products to improve the healing of complex wounds and soft tissue reconstruction.

    The company's principal market is the United States where it markets four key products targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.

    Its first wound-healing product Endoform was approved by the US Food & Drug Administration (FDA) in 2013. Aroa's first commercial surgical product, a reinforced bioscaffold developed in collaboration with US company Tela Bio Inc., was approved by the FDA in 2014.

     

    ARX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 Nov 2023 $0.72 $0.01 1.40% 280,075 $0.72 $0.76 $0.71
    28 Nov 2023 $0.72 $-0.01 -1.39% 287,926 $0.75 $0.78 $0.72
    27 Nov 2023 $0.72 $0.05 7.46% 125,755 $0.69 $0.74 $0.69
    24 Nov 2023 $0.67 $-0.05 -6.94% 1,437,152 $0.71 $0.71 $0.67
    23 Nov 2023 $0.72 $0.05 7.46% 85,596 $0.67 $0.72 $0.66
    22 Nov 2023 $0.67 $0.00 0.00% 126,369 $0.65 $0.67 $0.63
    21 Nov 2023 $0.67 $-0.02 -2.92% 477,095 $0.68 $0.70 $0.64
    20 Nov 2023 $0.69 $-0.01 -1.43% 1,113,631 $0.70 $0.70 $0.69
    17 Nov 2023 $0.70 $-0.02 -2.80% 74,448 $0.72 $0.72 $0.70
    16 Nov 2023 $0.72 $-0.04 -5.33% 1,408,303 $0.75 $0.75 $0.70
    15 Nov 2023 $0.75 $0.00 0.00% 43,371 $0.75 $0.75 $0.73
    14 Nov 2023 $0.75 $0.02 2.72% 74,541 $0.74 $0.75 $0.74
    13 Nov 2023 $0.74 $-0.04 -5.19% 48,421 $0.78 $0.78 $0.74
    10 Nov 2023 $0.77 $-0.03 -3.77% 13,250 $0.80 $0.80 $0.77
    09 Nov 2023 $0.80 $-0.01 -1.25% 28,115 $0.80 $0.80 $0.79
    08 Nov 2023 $0.80 $-0.01 -1.23% 23,803 $0.82 $0.82 $0.77
    07 Nov 2023 $0.82 $-0.01 -1.22% 211,278 $0.82 $0.82 $0.78
    06 Nov 2023 $0.82 $0.00 0.00% 1,346,523 $0.84 $0.84 $0.82
    03 Nov 2023 $0.82 $0.03 3.80% 95,829 $0.79 $0.84 $0.79
    02 Nov 2023 $0.79 $0.01 1.28% 81,312 $0.76 $0.79 $0.74
    01 Nov 2023 $0.78 $0.01 1.29% 82,230 $0.78 $0.78 $0.73
    31 Oct 2023 $0.78 $0.03 4.03% 18,813 $0.78 $0.78 $0.76

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Sep 2023 James (Jim) McLean Exercise 50,000 $37,500
    Exercise of options.
    06 Sep 2023 James (Jim) McLean Buy 50,000 $37,500
    Exercise of options.
    11 Aug 2023 Catherine Mohr Issued 210,686 $185,403
    Issue of options.
    31 Mar 2023 Steven (Steve) Engle Issued 172,620 $181,251
    Issue of options.
    31 Mar 2023 John Pinion II Issued 172,620 $181,251
    Issue of options.
    31 Mar 2023 Brian Ward Issued 2,575,483 $2,704,257
    Issue of options.
    31 Mar 2023 John Diddams Issued 172,620 $181,251
    Issue of options.
    31 Mar 2023 Philip McCaw Issued 172,620 $181,251
    Issue of options.
    31 Mar 2023 James (Jim) McLean Issued 258,929 $271,875
    Issue of options.
    14 Dec 2022 John Diddams Issued 20,452 $22,292
    Issue of options.
    14 Dec 2022 John Diddams Exercise 165,000 $17,732
    Exercise of options. NZ$
    14 Dec 2022 John Diddams Buy 165,000 $17,732
    Exercise of options. NZ$

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr John Flower Diddams Non-Executive Director Nov 2019
    Mr Diddams is a resident of Australia and has over forty years of experience as a CFO, CEO, and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in several diverse industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors.
    Mr Philip John McCaw Non-Executive Director Mar 2008
    Mr McCaw is a resident of New Zealand and is the Founding Partner of Movac, one of New Zealands Venture Capital funds. He led the original investment round into AROA in 2008, has worked closely with the Company and has served on the Board since then. He is also Chair of the New Zealand Government's Startup Advisors Council, established to help identify and address the opportunities and challenges facing high growth start-up businesses. Phil has over 20 years of experience investing into New Zealand technology companies and helping to guide their growth. He was an early investor in Trade Me, New Zealand's leading on-line trading community, which was sold to Fairfax in 2006.
    Mr James (Jim) Neil McLean Non-Executive ChairmanNon-Executive Director Aug 2011
    Mr McLean is a resident of New Zealand. He has over 25 years of experience serving as chair, director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to AROA, current appointments include Chair of Prevar Limited and R J Hill Laboratories. He was Chair of the New Zealand Institute of Plant and Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as Deputy Chair. Jim was an executive and director of Genesis Research and Development Corporation during its early stages through to public listing.
    Mr Steven (Steve) Barnard Engle Non-Executive Director Apr 2015
    Mr Engle is a resident of the US. He has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic, and infectious disease areas. Steve is the CEO and executive director of Gradalis Inc a late-stage biopharmaceutical company focused on the development and commercialisation of personalized therapeutics to treat cancer. He is also the non-executive Chairman of the board of Prescient Therapeutics an ASX listed clinical stage oncology company, and executive Chairman of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. Steve also runs Averigon, an advisory firm to the life science industry on matters ranging from business development to management team coaching. He is also member of the Risk Committee.
    Mr John Richard Pinion II Non-Executive Director Feb 2015
    Mr Pinion II is a resident of the US. He has over 30 years of global experience leading biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe, and the Americas. His expertise and leadership spans engineering, quality, manufacturing, and translational sciences. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical QC. He is also Chair of Risk committee.
    Mr Brian Roderick Ward Chief Executive OfficerManaging Director Sep 2007
    Mr Ward is the founder of AROA and a resident of New Zealand. He has held senior corporate roles in life sciences and health care companies for more than 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development, and strategy having worked for several multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on several government and industry expert panels. Brian has been responsible for leading AROA's growth from start-up through to the present.
    Dr Catherine Mohr Non-Executive Director Nov 2022
    Dr Mohr is a New Zealand citizen and resident of the US. She has over 30 years of experience across fields, including engineering, healthcare, alternative energy, aerospace, and global entrepreneurship. Her expertise spans many areas related to AROA's next stage of growth, including medtech product research and development, FDA approvals, product commercialisation and surgery technology innovation. She has been President of the Intuitive Foundation since 2018. Prior to leading the Foundation, Catherine held senior roles at Intuitive Surgical, including Vice President of Strategy and Director of Medical Research. Intuitive Surgical is a pioneer in the robotic-assisted surgery field and developed the da Vinci surgical robotic system which is used in millions of surgical procedures across the globe every year. She is also a member of risk committee.
    Ms Tracy Weimar Joint Company Secretary Jul 2020
    -
    Mr James Blair Agnew Chief Financial OfficerJoint Company Secretary
    -
    James Blair Agnew Chief Financial OfficerJoint Company Secretary
    -
    Barnaby May Chief Scientific Officer
    -
    Patrick Hunt Director of Business Development
    -
    Frazer Murray Director of Global Marketing and Strategy
    -
    Rachel Stuart Director of People and Culture
    -
    Neetha Alex-Kumar General Counsel
    -
    Tracy Weimar Joint Company Secretary
    -
    Brad Adams VP - Commercial (USA)
    -
    Rod Stanley VP - Manufacturing Operations
    -
    Isaac Mason VP - Product Development
    -
    Yasmin Winchester VP - Quality Regulatory and Sustainability
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 47,694,722 13.90%
    Mr Brian Ward & Mrs Tracey Ward <Arawai No 2 A/C> 33,125,800 9.65%
    J P Morgan Nominees Australia Pty Limited 31,448,545 9.17%
    HSBC Custody Nominees (Australia) Limited 24,111,683 7.03%
    National Nominees Limited 20,287,882 5.91%
    Phil Mccaw <Mcsyth Capital Invest A/C> 19,751,154 5.75%
    Richard Abbott <Jester 002 Investment A/C> 13,043,020 3.80%
    Aspire Nz Seed Fund Ltd 12,689,627 3.70%
    BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 10,422,463 3.04%
    BNP Paribas Noms (Nz) Ltd <Drp> 8,261,303 2.41%
    Custodial Services Limited <Beneficiaries Holding A/C> 6,846,246 2.00%
    Bnp Paribas Noms Pty Ltd <Drp> 6,682,320 1.95%
    K One W One (No 3) Ltd 5,882,550 1.71%
    Sharon Bryant <Ot Investment A/C> 4,372,267 1.27%
    Christopher David Astley Milne 3,213,022 0.94%
    K One W One Ltd 3,041,226 0.89%
    Gft 2 Co Pty Limited <Gft 2 A/C> 2,820,912 0.82%
    James Mclean 2,777,108 0.81%
    Mesynthes Nominees Ltd 2,568,600 0.75%
    Barnaby May 2,449,500 0.71%

    Profile

    since

    Note